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Presence of individual (residual) symptoms during
depressive episodes and periods of remission: a
3-year prospective study
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Background. Residual depressive symptomatology constitutes a substantial risk for relapse in depression. Treatment
until full remission is achieved is therefore implicated. However, there is a lack of knowledge about the prevalence of
(1) residual symptoms in general and (2) the individual residual symptoms in particular.
Method. In a 3-year prospective study of 267 initially depressed primary care patients we established per week the
presence/absence of the individual DSM-IV depressive symptoms during subsequent major depressive episodes
(MDEs) and episodes of (partial) remission. This was accomplished by means of 12 assessments at 3-monthly
intervals with the Composite International Diagnostic Interview (CIDI).
Results. In general, residual depressive symptomatology was substantial, with on average two symptoms present
during remissions. Three individual symptoms (cognitive problems, lack of energy and sleeping problems)
dominated the course of depression and were present 85–94% of the time during depressive episodes and 39–44% of
the time during remissions.
Conclusions. Residual symptoms are prevalent, with some symptoms being present for almost half of the time
during periods of remission. Treatment until full remission is achieved is not common practice, yet there is a clear
need to do so to prevent relapse. Several treatment suggestions are made.
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Introduction
Although psychological and pharmacological treat-
ments for depression are capable of reducing relapse
rates, incomplete remission after treatment is common
(Thase et al. 1992; Paykel et al. 1995 ; Fava et al. 1998,
2004). This is problematic because residual depressive
symptomatology constitutes a serious risk for relapse
and even a subsequent chronic course (Ormel et al.
1993 ; Paykel et al. 1995 ; Judd et al. 2000). For example,
residual subsyndromal depression has been associ-
ated with an odds ratio of 3.5 for patients with sub-
sequent relapse comparedwith thosewho experienced
full recovery (Judd et al. 1998). Therefore, treatment
until full remission has been achieved is implicated
(cf. Thase et al. 1992 ; APA, 2000). Such enhanced
treatment may prevent residual symptoms from de-
veloping into prodromes of relapse, as has been dem-
onstrated by Fava et al. (1998, 2004) and Paykel et al.
(1999, 2005). However, to be able to improve treat-
ment, information is needed concerning : (1) the
prevalence of residual symptoms in general, and
consequently the necessity for treatment of residual
symptomatology, and (2) which of the individual de-
pressive symptoms usually remain as residual symp-
toms.
A systematic literature search (see Method) re-
vealed several studies that examined the presence of
individual depressive symptoms during major de-
pressive episodes (MDEs) (Chen et al. 2000 ; Kornstein
et al. 2000 ; Minor et al. 2005 ; Pettit et al. 2006 ; Gaynes
et al. 2007 ; Nierenberg et al. 2007 ; Gaudiano et al. 2008;
Smith et al. 2008). However, with regard to periods of
remission, or non-depressive episodes (non-MDEs),
similar studies are rare (Minor et al. 2005). In addition,
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the limitations of most of the studies that did examine
individual depressive symptoms are fourfold. First, all
studies are based on cross-sectional data, that is the
absence or presence of individual depressive symp-
toms was established at only one point in time. This
means that, depending on the speciﬁc moment
during the episode that patients are assessed, the
presence of symptomsmay be over- or underestimated
(Patten, 2009). To prevent systematic bias, a proper
assessment of the actual variability of the long-term
course can best be performed by prospective longi-
tudinal measurements on a regular basis. Second,
although most studies assessed the presence of
symptoms during a current MDE (Kornstein et al.
2000 ; Minor et al. 2005 ; Pettit et al. 2006 ; Gaynes et al.
2007 ; Nierenberg et al. 2007 ; Gaudiano et al. 2008),
some determined symptom proﬁles retrospectively
during a worst-ever episode (Chen et al. 2000 ; Smith
et al. 2008), which may have resulted in biased
reports. Third, very few of those studies examined the
absence and presence of individual symptoms during
both MDEs and non-MDEs within the same patients.
This is important because only in this way can
the relative contribution of individual symptoms
across MDEs and non-MDEs be determined. The
only exception is the study by Minor et al. (2005), but
this concerns a relatively small out-patient sample
(n=35) with assessments at only two points in time.
Fourth, only the study by Gaynes et al. (2007) was
aimed at primary care patients ; this is important
because the vast majority of depressive patients
are treated in this setting. Unfortunately, they only
reported symptom prevalence during MDEs and not
during non-MDEs.
In the current study we addressed these four prob-
lems. First, the presence of each individual DSM-IV
depressive symptom was assessed at 13 points in time
to obtain a week-by-week record of the presence of the
individual depressive symptoms. Second, the study
was conducted prospectively during a 3-year follow-
up. Third, assessment was undertaken during both
MDEs and non-MDEs within the same patients.
Fourth, a substantial sample of primary care patients
was examined. We compared our results with those of
other studies that we obtained by a systematic litera-
ture search.
Method
Setting, patients and inclusion criteria
Patients participated in the Interventie Studie Eerste
Lijn (INSTEL), a randomized clinical trial in primary
care evaluating the eﬀects of four treatments (for de-
tails see Conradi et al. 2007). We included patients
referred by GPs who were treating them for de-
pression, were aged between 18 and 70 years, and
were not suﬀering from a life-threatening medical
condition, psychotic disorder, bipolar disorder, de-
mentia or primary alcohol or drug dependency.
Additional exclusion criteria were pregnancy and al-
ready receiving psychotherapy.
The trial consisted of four interventions : usual care
by the GP (UC; n=72), a psycho-educational pre-
vention program (PEP; n=112), and PEP plus either
psychiatric consultation (PC+PEP; n=39) or brief
cognitive behavioral therapy (CBT+PEP; n=44). UC
consisted of brief supportive counseling, possible anti-
depressant prescription and/or referral according to
clinical guidelines. PEP was a low-intensity program
consisting of three face-to-face sessions and short
3-monthly telephone contacts thereafter. In the
PC+PEP condition, one session with a psychiatrist
preceded PEP, whereas in CBT+PEP, on average 10
sessions of CBT were provided prior to PEP. After a
complete description of the study to the subjects,
written informed consent was obtained.
Instrument
At baseline, the Composite International Diagnostic
Interview (CIDI) version 2.1 (WHO, 1997; Ter Smitten
et al. 1998) was administered face to face. The CIDI is a
structured psychiatric interview that has shown good
reliability and validity (Wittchen, 1994 ; Kessler et al.
2004). After baseline, patients were interviewed at
3-monthly intervals by telephone, the interview in-
cluding an adapted CIDI depression section. By this
means we established the presence or absence of each
of the individual DSM-IV criteria, or symptom clus-
ters, of depression per week in the past 3 months. Item
parcels were created by counting the symptom group
as present if any one of the symptoms forming
the DSM-IV criterion were present. These symptom
clusters include the two core symptoms, namely de-
pressed mood (feeling sad or empty) and/or dimin-
ished interest and pleasure in activities (anhedonia),
and the seven other symptom clusters : eating prob-
lems (weight gain or loss and/or increases or de-
creases of appetite), sleeping problems (insomnia or
hypersomnia), psychomotor problems (psychomotor
agitation or retardation), fatigue or loss of energy,
worthlessness and/or guilt (not merely self-reproach
or guilt about being depressed), cognitive problems
(diminished ability to think or concentrate and/or in-
decisiveness) and death ideations (recurrent thoughts
of death and suicide). Based on these data on the
week-by-week presence of these individual symp-
toms, we were able to establish whether patients were
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meeting the criteria for MDE for each week during the
entire follow-up period.
Outcome measures and analyses
We deﬁned MDEs in accordance with DSM-IV dur-
ation and severity criteria, that is o2 consecutive
weeks in which the patient suﬀered the majority of the
day from at least ﬁve of the DSM-IV-deﬁned depress-
ive symptoms, including at least one of the core
symptoms. Consequently, the periods when patients
did not suﬀer from DSM-IV-deﬁned MDEs were
labeled as non-MDEs. In these periods patients may
have suﬀered from residual symptoms.
We computed for each distinct period of MDE and
non-MDE the proportion of time patients reported the
presence of each of the individual DSM-IV symptom
clusters. These proportions of time that patients met
criteria for each of the individual symptoms were
added for each distinct MDE and non-MDE, to com-
pute a measure for the overall (residual) severity
during these periods.
Finally, we performed sensitivity analyses to rule
out possible treatment eﬀects explaining our ﬁndings.
In the original study (Conradi et al. 2007), no diﬀer-
ences were found between treatments during the
3-year follow-up on any of the CIDI-based outcomes,
which was the measure of interest in this study.
However, a relatively small diﬀerence emerged on
the Beck Depression Inventory (BDI) between UC and
PEP compared with PC+PEP and CBT+PEP. There-
fore, we made comparisons by means of Wilcoxon
non-parametric tests between these two subgroups of
patients on the proportions of time the individual
CIDI-based symptoms were present. The signiﬁ-
cance level for the analyses was set at p<0.05 (two-
tailed).
Comparison with other studies
To compare our ﬁndings with other studies, we per-
formed a systematic search of the research literature.
The following search terms were entered in Medline :
‘ (residual) symptom* (proﬁle*) depression’. Stars
represent wild cards, and the terms in parentheses
were systematically entered and left out in all possible
combinations with the other terms. In this way we
were able to cover research concerning the presence
of symptoms during MDEs and non-MDEs. This
search resulted in the studies mentioned in the
Introduction.
To examine comparability, we computed
Spearman’s non-parametric correlation coeﬃcient
(r) between the rankings of the prevalences of the
depressive symptoms during MDEs and non-MDEs in
our study and each of the other studies.
Results
Patient characteristics and non-response at
assessments
Sociodemographic and clinical characteristics of the
sample are displayed in Table 1. There were no dif-
ferences between treatment groups on these baseline
characteristics, apart from the ﬁnding that signiﬁ-
cantly more UC patients were married compared to
CBT+PEP patients (F=8.08, p=0.044), and somewhat
more UC patients reported severe depressions at
baseline compared to PEP patients (F=7.76, p=0.021).
Non-response for the 12 3-monthly telephone inter-
views ranged from approximately 8% to on average
20%. To test whether low responders (i.e. patients who
were followed up for <27 weeks) diﬀered from the
other patients, we compared them on several import-
ant characteristics assessed on baseline. These in-
cluded: gender, age, age of ﬁrst-onset MDE, use of
antidepressants, number of prior MDEs, MDE severity
on the CIDI, severity of depression on the BDI and the
Table 1. Sociodemographic and clinical characteristics at
baseline (n=267)



















Recurrent episode (DSM-IV) 67.2
More than three previous episodes (DSM-IV) 36.8
Antidepressant medication 74.2
Co-morbid anxiety disorder (DSM-IV) 37.8
Values given as percentage or mean¡standard deviation.
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Symptom Checklist (SCL)-90, and average score
on Neuroticism on the NEO Five-Factor Inventory
(NEO-FFI). As no statistically signiﬁcant diﬀer-
ences were found, we included all patients in our
analyses.
Three-year course of depressive symptoms
Figure 1 displays the detailed course of the individual
depressive symptoms during the 3-year follow-up,
during MDEs and non-MDEs. Nearly all patients were
suﬀering from a MDE at entry of the study, as is re-
ﬂected by the high prevalence of most of the symp-
toms at baseline.
Table 2 (ﬁrst column) displays the proportions of
time the individual symptoms were present during
total follow-up. Three groups of symptoms are dis-
cernable. Cognitive problems, lack of energy, sleeping
problems and depressed mood/diminished interest
were present 58–66% of the time during the total fol-
low-up in this initially depressed primary care sample.
Eating problems and feelings of worthlessness/guilt
were present 36% and 45% of the time respectively,
and the least prevalent symptoms were recurrent
thoughts of death and psychomotor problems, with
24% for both. Overall severity was 4.1, meaning that on
average about four symptoms were present all of the
time during follow-up. There were no statistically sig-
niﬁcant diﬀerences between UC and PEP patients on
the one hand and PC+PEP and CBT+PEP patients on
the other.
The presence of individual symptoms during MDEs
and non-MDEs
Table 2 also shows the proportions of time that indi-
vidual symptoms were present for the periods during
total follow-up when patients met DSM-IV criteria of
MDE, and for the periods when patients did not meet
criteria for the diagnosis (non-MDE). The core symp-
toms, by deﬁnition present 100% of the time during
MDEs, were present 21% of the time during non-
MDEs. Apart from the core symptoms, the three
groups of symptoms described above were present
during both MDEs and non-MDEs. Again, cognitive
problems, lack of energy and sleeping problems were
the most prevalent, ranging from 85% to 94% of the
time present during the combined MDEs and from
35% to 44% of the time during non-MDEs. Feelings of
worthlessness/guilt and eating problems were pres-
ent 70% and 53% of the time respectively during
combined MDEs, and 22% and 21% of the time during
non-MDEs. Finally, recurrent thoughts of death and
psychomotor problems were again the least prevalent
symptoms, with 37% and 35% respectively during
MDEs, and 11% and 14% during the depression-free
time. During the combinedMDEs, overall severity was






































































Fig. 1. The presence of DSM-IV depressive symptom clusters during the 3-year follow-up.
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all of the MDE follow-up time, whereas during the
combined non-MDEs the overall residual severity was
2.1. Again, no statistically signiﬁcant diﬀerences were
observed between UC and PEP patients on the one
hand and PC+PEP and CBT+PEP patients on the
other.
Comparisons with other studies
Tables 3 and 4 display the proportions of time the in-
dividual depressive symptoms were present during
MDEs and non-MDEs respectively, as reported by the
studies found by our systematic literature search. Of
particular interest are Spearman’s correlation coef-
ﬁcients, which were computed between the ranking
orders of the symptoms of our study and each of the
other studies. With regard to studies reporting symp-
tom prevalences during MDEs, the correlations with
our study were statistically signiﬁcant (p<0.01, two-
tailed) for the non-retrospective studies and range
between 0.88 and 0.99. Correlations with the two
retrospective studies were lower (0.83, p=0.011, two-
tailed ; Smith et al. 2008) or not statistically signiﬁcant
(Chen et al. 2000). The correlation between our study
and the only other study we found on residual symp-
toms during a non-MDE (Smith et al. 2008) was 0.77
(p=0.027, two-tailed).
Discussion
In this study (residual) depressive symptomatology
was examined in a 3-year prospectively followed
sample of primary care patients. Patients in this setting
are understudied, but from a clinical point of view
they are very important because the vast majority
of depressed patients are treated in primary care. Two
conclusions may be drawn. First, in general, residual
symptomatology is substantial, with more than two
DSM-IV symptom clusters present during total non-
MDE follow-up time. Second, at the level of the indi-
vidual residual symptoms, cognitive problems, lack of
energy and sleeping problems dominated the course
of depression. They were present 85–94% of the time
during MDEs and 39–44% of the time during non-
MDEs.
Strengths and limitations
One limitation of this study is that we did not diﬀer-
entiate between depressed mood and diminished in-
terest. It may be of interest to examine whether one of
the core symptoms is more responsible than the other
for the diﬀerence in prevalence of the combined core
symptoms during MDEs and non-MDEs. However, as
both depressed mood and diminished interest refer to
restricted motivation, we do not consider this to be
crucial from a clinical point of view. Another limi-
tation may be that we did not assess severity of the
individual symptoms present ; instead we assessed
duration of presence. Finally, although patients par-
ticipated in a randomized controlled trial, we ruled
out possible treatment eﬀects by testing whether
treatment condition was associated with the pro-
portion of time individual symptoms were present.
This seemed not to be the case. This lack of diﬀerence
between treatments concerning residual symptoms is
not surprising because, in the main study, there were
no diﬀerences between treatments on CIDI total
symptom severity (Conradi et al. 2007).
An important strength of our study is the unpre-
cedented detailed insight into the prospective 3-year
course of individual depressive symptoms, which we
obtained bymeans of the week-by-week establishment
Table 2. Duration of presence of DSM-IV (residual) symptoms during major depressive episodes (MDEs) and non-major depressive
periods (non-MDEs)
Proportion of time that patients met DSM-IV criteria per symptom cluster
During total follow-up MDEs (n=481) Non-MDEs (n=497)
Depressed mood/diminished interest 0.58 (0.25) ; 0.56 (0.50–0.72) 1.00 (0.00) ; 1.00 (1.00–1.00) 0.21 (0.27) ; 0.08 (0.00–0.36)
Cognitive problems 0.66 (0.30) ; 0.71 (0.50–0.97) 0.94 (0.20) ; 1.00 (1.00–1.00) 0.44 (0.37) ; 0.40 (0.08–0.78)
Lack of energy 0.60 (0.29) ; 0.61 (0.46–0.83) 0.90 (0.23) ; 1.00 (0.98–1.00) 0.35 (0.34) ; 0.24 (0.02–0.61)
Sleeping problems 0.61 (0.30) ; 0.63 (0.43–0.85) 0.85 (0.27) ; 1.00 (0.77–1.00) 0.39 (0.34) ; 0.32 (0.07–0.65)
Worthlessness/guilt 0.45 (0.32) ; 0.46 (0.15–0.68) 0.70 (0.36) ; 0.91 (0.45–1.00) 0.22 (0.30) ; 0.05 (0.00–0.42)
Eating problems 0.36 (0.31) ; 0.32 (0.05–0.57) 0.53 (0.39) ; 0.57 (0.13–0.99) 0.21 (0.28) ; 0.07 (0.00–0.36)
Psychomotor problems 0.24 (0.29) ; 0.09 (0.00–0.41) 0.35 (0.37) ; 0.23 (0.00–0.67) 0.14 (0.26) ; 0.00 (0.00–0.13)
Death ideations 0.24 (0.29) ; 0.09 (0.00–0.42) 0.37 (0.39) ; 0.25 (0.00–0.71) 0.11 (0.22) ; 0.00 (0.00–0.09)
Overall severity (range 0–9) 4.13 (1.65) ; 4.21 (3.36–5.00) 6.39 (0.88) ; 6.36 (5.71–7.00) 2.12 (1.36) ; 2.06 (0.98–3.18)
Values are given as mean (standard deviation) ; median (interquartile range).
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Table 3. The presence of DSM-IV symptoms (%) during major depressive episodes (MDEs) in reviewed studies
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Percentage of patients with symptom present during MDE
Depressed mood/
diminished interesta
100 100 100 100 100 100 100 100 100 100 100 100
Cognitive problems 88.5 91.8 89.8 90.7 83.2 87.2 88.5 80.7 97d 77d 77d 94.0
Lack of energy 89.9 88.4 89.4 90.2 77.7 95.1 86.0 87.0 97d 72d 55d 90.0
Sleeping problemsb 83.0c 77.2c 81.4c 80.7c 82.1 81.1 66.5 54.4c 69c,d 83d 79d 85.0
Worthlessness/guilt 76.6 82.5 79.0 82.1 80.5 80.2 66.5 59.1 93d 67d 42d 70.0
Eating problemsb 42.7c 44.3c 45.4c 44.5c 72.0 52.7 63.5 43.4c 73c,d 70d 70d 53.0
Psychomotor problemsb 62.1c 64.5c 62.9c 63.0c 61.2 47.1 44.0 30.2c 49c,d 47d 37d 35.0
Death ideations 42.8 51.4 47.3 48.6 43.1 45.0 49.0 49.4 87d 82d 60d 37.0
Spearman’s r with
present study
0.88** 0.88** 0.91** 0.88** 0.91** 0.95** 0.99** 0.93** 0.83* 0.62 0.69 –
STAR*D, Sequenced Treatment Alternatives to Relieve Depression Study ; ECA, Epidemiologic Catchment Area Program; INSTEL, Interventie Studie Eerste Lijn (Intervention
Study Primary Care) ; DD, double depression (i.e. MDE superimposed on dysthymia) ; IDS, Inventory of Depressive Symptomatology ; K-SADS, Schedule for Aﬀective Disorders
and Schizophrenia for School-Age Children ; SCID, Structured Clinical Interview for DSM; SCAN, Schedules for Clinical Assessment in Neuropsychiatry ; DIS, Diagnostic Interview
Schedule ; CIDI, Composite International Diagnostic Interview.
a By deﬁnition 100%.
b In some studies no data are available regarding the DSM-IV criterion score but only regarding the constituting facets (i.e. sleeping problems : onset, nocturnal and early morning
insomnia, and hypersomnia ; eating problems : appetite decrease and increase and weight decrease and increase ; and psychomotor problems : retardation and agitation). We report
the highest facet score as the minimal parcel score (c) on the corresponding DSM-IV criterion.
d Approximate score derived from graphical data.









of the presence of individual symptoms with 12
3-monthly interviews. The studies mentioned in
the Introduction assessed the presence of individual
symptoms at a single moment in time. This resulted in
percentages of patients who were reporting the pres-
ence of individual symptoms, whereas we were able
to establish the mean percentages of time that indi-
vidual symptoms were present in patients during
(non-)MDEs. Another strength of our study is that we
analyzed individual symptoms in a sample of patients
in primary care, the setting in which the majority of
depressed patients are treated. This has not been done
before during both MDEs and non-MDEs.
Generalizability issues
The comparisons between our studies and others
(Tables 3 and 4) lead us to make several remarks. First,
Spearman’s correlation coeﬃcients between the rank-
ing order of individual depressive symptoms of our
study and those of the other non-retrospective studies
during MDEs are all high and statistically signiﬁcant.
Although there are some variations in the overall
pattern, this means that the ranking order of pre-
valences of our study is rather comparable with those
of larger samples, suggesting that the prevalences of
symptoms we found during non-MDEs may be gen-
eralizable to larger samples too. This is corroborated
by the statistically signiﬁcant correlation with the only
available, but much smaller, study on symptom pre-
valences during non-MDEs in formerly depressed
patients (Smith et al. 2008).
Second, the statistically non-signiﬁcant correlations
we have found are telling as well. This concerns one
of the studies retrospectively reporting symptom
prevalences during the worst MDEs. This may mean
that the worst MDEs are less comparable with the
average MDEs, or retrospectively reported symptom
prevalences are biased.
Third, when comparing the cross-sectionally ob-
tained symptom prevalences in Table 3 with the pro-
spective percentages of the INSTEL study, several
diﬀerences stand out. When looking at only diﬀer-
ences in prevalence of approximately 20%, the INSTEL
Table 4. The presence of DSM-IV residual symptoms (%) during non-major depressive
episodes (non-MDEs)
Minor et al. 2005 Present study
Study INSTEL
n 35 267
Patients Out-patients Primary care
Instrument SCID CIDI
Method Cross-sectional 3-year prospective









Cognitive problems 46.0 44.0
Lack of energy 37.0 35.0
Sleeping problems 29.0 39.0
Worthlessness/guilt 17.0 22.0
Eating problems 37.0 21.0
Psychomotor problems 9.0 14.0
Death ideations 11.0 11.0
Spearman’s r with present study 0.77* –
INSTEL, Interventie Studie Eerste Lijn (Intervention Study Primary Care) ; SCID,
Structured Clinical Interview for DSM; CIDI, Composite International Diagnostic
Interview ; non-MDE, non-depressive episode.
a In the Minor et al. study no data are available regarding the DSM-IV overall
core symptoms score, but only regarding the distinct symptoms (i.e. depressed
mood and diminished interest), therefore we reported the highest symptom score
as the minimal score on the overall core symptom score.
* p<0.05 (two-tailed).
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primary care patients reported less psychomotor
problems than their counterparts in the STAR*D
studies (>62% v. 35%), but on the other symptoms
seem rather comparable. In addition, the adolescents
in the Pettit et al. study (2006) reported more psycho-
motor problems too compared to INSTEL (61% v.
35%), and more eating problems (72% v. 53%). The
patients in Minor et al.’s study (2005) reported less
sleeping problems (66.5%) compared to the INSTEL
patients (85%). Finally, the percentages reported in the
small sample studies by Chen et al. (2000) and in the
study by Smith et al. (2008) are the most deviant from
all studies. This is possibly because of the retrospec-
tive nature of these studies, in which the lifetime worst
MDEs were subject to examination.
Finally, we found that not only were the ranking
orders of prevalences of symptoms during MDEs
comparable between our and other studies (Table 3),
as was the case regarding non-MDEs (Table 4), but
also within studies the ranking order of symptoms
during MDEs and non-MDEs proved to be fairly
similar. Apart from the core symptoms (which have
a diﬀerent status because of the deﬁnition of MDE
in DSM-IV), Spearman’s correlation coeﬃcient of the
symptom rankings between MDEs and non-MDEs
was 0.93 (p=0.003, two-tailed) in the INSTEL study
and 0.84 (p=0.019, two-tailed) in the Minor et al. study
(2005). Thus, a markedly stable ranking of symptom
prevalences was revealed across the diﬀerent phases
(i.e. MDEs and non-MDEs) of the depressive course.
There is no pattern of randomly waxing and waning of
symptoms, but there seems to be a steady presence of
speciﬁc symptoms over time in which (residual)
symptoms, such as cognitive problems of poor con-
centration and indecisiveness and the more physical
symptoms of lack of energy and sleeping problems,
dominate.
Clinical implications
With this prospective study we were able to answer
the two questions posed in the Introduction : (1) how
prevalent are residual depressive symptoms in gen-
eral, and (2) which of the individual depressive
symptoms usually remain as residual symptoms?
First, we have found fairly high rates of overall re-
sidual symptomatology, especially when taking into
account that these are average rates over longer
periods. During non-MDEs, on average the criteria for
two DSM-IV depressive symptom clusters were met at
any point of time. This means that the notion of de-
pression as a chronic disease becomes inevitable. Par-
tial remission is very common and constitutes a great
challenge in clinical practice. Therefore, treatment
should be further augmented to reduce residual
symptoms and risk of relapse.
Second, looking at which speciﬁc individual symp-
toms are responsible for these high residual symptom
rates, cognitive problems (poor concentration and in-
decisiveness), lack of energy, and sleeping problems
with prevalences ranging from 35% to 44%, stand out.
These symptoms are in need of continuous preventive
attention to prevent the return of MDEs. From that
perspective it is noteworthy that cognitive therapy
is able to reduce cognitive symptomatology by at
maximum two-thirds compared to usual care by the
GP (Conradi et al. 2008). With regard to lack of energy
and sleeping problems, regular physical exercise
may be an eﬀective way to enhance physical ﬁtness in
depressed patients (Blumenthal et al. 1999 ; Babyak
et al. 2000) and reduce tiredness and promote more
healthy sleep. Reduction of cognitive problems may
also have a positive eﬀect on sleeping by decreasing
possible ruminative processes. Although the core de-
pressive symptoms are less prevalent during re-
missions, negative aﬀect and anhedonia may have a
deleterious impact on the patients’ motivation to
stay active (i.e. exercising and undertaking formerly
pleasurable activities), which is crucial in preventing
relapse. Behavioral activation tackles such motiv-
ational problems by training patients not to wait until
they ‘ feel like ’ undertaking activities, but conversely
to get active in order to regain pleasure in those ac-
tivities, lift anhedonia and improve mood. Behavioral
activation is a promising treatment (Dimidjian et al.
2006) with enduring eﬀects (Dobson et al. 2008). How-
ever, physicians need to be alert regarding the less
prevalent residual symptoms, such as eating prob-
lems, feelings of worthlessness/guilt, psychomotor
problems and recurrent thoughts of death. Although
less prevalent, these symptoms may constitute a
higher risk of relapse. This should be examined in
future studies.
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